Lineage Cell Therapeutics/$LCTX
1D1W1MYTD1Y5YMAX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
- Ticker
- $LCTX
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 75
- Headquarters
- Carlsbad, United States
- Website
- www.lineagecell.com
LCTX Metrics
BasicAdvanced
$281M
-
-$0.19
1.55
-
Price and volume
Market cap
$281M
Beta
1.55
52-week high
$2.09
52-week low
$1.00
Average daily volume
954K
Financial strength
Current ratio
6.608
Quick ratio
6.46
Long term debt to equity
2.254
Total debt to equity
3.845
Profitability
EBITDA (TTM)
-26.111
Gross margin (TTM)
-57.36%
Net profit margin (TTM)
-246.58%
Operating margin (TTM)
-205.23%
Effective tax rate (TTM)
14.12%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-17.04%
Return on equity (TTM)
-60.06%
Valuation
Price to revenue (TTM)
20.375
Price to book
4.61
Price to tangible book (TTM)
15.14
Price to free cash flow (TTM)
-10.929
Free cash flow yield (TTM)
-9.15%
Free cash flow per share (TTM)
-0.102
Growth
Revenue change (TTM)
19.87%
Earnings per share change (TTM)
0.15%
3-year revenue growth (CAGR)
7.52%
10-year revenue growth (CAGR)
6.29%
3-year earnings per share growth (CAGR)
12.58%
10-year earnings per share growth (CAGR)
-2.21%
What the Analysts think about LCTX
Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.
LCTX Financial Performance
Revenues and expenses
LCTX Earnings Performance
Company profitability
LCTX News
AllArticlesVideos
Lineage Cell Therapeutics Q2 Earnings Call Highlights
MarketBeat3 weeks ago
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan
MarketBeat2 months ago
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.